TY - JOUR
T1 - Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator
T2 - The DAI-T4F Nationwide Registry
AU - DAI-T4F Investigators
AU - Waldmann, Victor
AU - Bouzeman, Abdeslam
AU - Duthoit, Guillaume
AU - Koutbi, Linda
AU - Bessiere, Francis
AU - Labombarda, Fabien
AU - Marquié, Christelle
AU - Gourraud, Jean Baptiste
AU - Mondoly, Pierre
AU - Sellal, Jean Marc
AU - Bordachar, Pierre
AU - Hermida, Alexis
AU - Anselme, Frédéric
AU - Asselin, Anouk
AU - Audinet, Caroline
AU - Bernard, Yvette
AU - Boveda, Serge
AU - Bru, Paul
AU - Bun, Sok Sithikun
AU - Clerici, Gael
AU - Da Costa, Antoine
AU - de Guillebon, Maxime
AU - Defaye, Pascal
AU - Elbaz, Nathalie
AU - Eschalier, Romain
AU - Garcia, Rodrigue
AU - Guenancia, Charles
AU - Guy-Moyat, Benoit
AU - Halimi, Franck
AU - Irles, Didier
AU - Iserin, Laurence
AU - Jourda, François
AU - Ladouceur, Magalie
AU - Lagrange, Philippe
AU - Laredo, Mikael
AU - Mansourati, Jacques
AU - Massoulié, Grégoire
AU - Mathiron, Amel
AU - Maury, Philippe
AU - Messali, Anne
AU - Narayanan, Kumar
AU - Nguyen, Cédric
AU - Ninni, Sandro
AU - Perier, Marie-Cécile
AU - Pierre, Bertrand
AU - Pujadas, Penelope
AU - Sacher, Frédéric
AU - Sagnol, Pascal
AU - Sharifzadehgan, Ardalan
AU - Walton, Camille
N1 - Publisher Copyright:
© 2020 American Heart Association, Inc.
Copyright:
Copyright 2022 Elsevier B.V., All rights reserved.
PY - 2020/10/27
Y1 - 2020/10/27
N2 - BACKGROUND: Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, and sudden cardiac death represents an important mode of death in these patients. Data evaluating the implantable cardioverter defibrillator (ICD) in this patient population remain scarce.METHODS: A Nationwide French Registry including all patients with tetralogy of Fallot with an ICD was initiated in 2010 by the French Institute of Health and Medical Research. The primary time to event end point was the time from ICD implantation to first appropriate ICD therapy. Secondary outcomes included ICD-related complications, heart transplantation, and death. Clinical events were centrally adjudicated by a blinded committee.RESULTS: A total of 165 patients (mean age, 42.2±13.3 years, 70.1% males) were included from 40 centers, including 104 (63.0%) in secondary prevention. During a median (interquartile range) follow-up of 6.8 (2.5-11.4) years, 78 (47.3%) patients received at least 1 appropriate ICD therapy. The annual incidence of the primary outcome was 10.5% (7.1% and 12.5% in primary and secondary prevention, respectively; P=0.03). Overall, 71 (43.0%) patients presented with at least 1 ICD complication, including inappropriate shocks in 42 (25.5%) patients and lead dysfunction in 36 (21.8%) patients. Among 61 (37.0%) patients in primary prevention, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patients with, respectively, 0, 1, 2, or ≥3 guidelines-recommended risk factors. QRS fragmentation was the only independent predictor of appropriate ICD therapies (hazard ratio, 3.47 [95% CI, 1.19-10.11]), and its integration in a model with current criteria increased the 5-year time-dependent area under the curve from 0.68 to 0.81 (P=0.006). Patients with congestive heart failure or reduced left ventricular ejection fraction had a higher risk of nonarrhythmic death or heart transplantation (hazard ratio, 11.01 [95% CI, 2.96-40.95]).CONCLUSIONS: Patients with tetralogy of Fallot and an ICD experience high rates of appropriate therapies, including those implanted in primary prevention. The considerable long-term burden of ICD-related complications, however, underlines the need for careful candidate selection. A combination of easy-to-use criteria including QRS fragmentation might improve risk stratification. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03837574.
AB - BACKGROUND: Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, and sudden cardiac death represents an important mode of death in these patients. Data evaluating the implantable cardioverter defibrillator (ICD) in this patient population remain scarce.METHODS: A Nationwide French Registry including all patients with tetralogy of Fallot with an ICD was initiated in 2010 by the French Institute of Health and Medical Research. The primary time to event end point was the time from ICD implantation to first appropriate ICD therapy. Secondary outcomes included ICD-related complications, heart transplantation, and death. Clinical events were centrally adjudicated by a blinded committee.RESULTS: A total of 165 patients (mean age, 42.2±13.3 years, 70.1% males) were included from 40 centers, including 104 (63.0%) in secondary prevention. During a median (interquartile range) follow-up of 6.8 (2.5-11.4) years, 78 (47.3%) patients received at least 1 appropriate ICD therapy. The annual incidence of the primary outcome was 10.5% (7.1% and 12.5% in primary and secondary prevention, respectively; P=0.03). Overall, 71 (43.0%) patients presented with at least 1 ICD complication, including inappropriate shocks in 42 (25.5%) patients and lead dysfunction in 36 (21.8%) patients. Among 61 (37.0%) patients in primary prevention, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patients with, respectively, 0, 1, 2, or ≥3 guidelines-recommended risk factors. QRS fragmentation was the only independent predictor of appropriate ICD therapies (hazard ratio, 3.47 [95% CI, 1.19-10.11]), and its integration in a model with current criteria increased the 5-year time-dependent area under the curve from 0.68 to 0.81 (P=0.006). Patients with congestive heart failure or reduced left ventricular ejection fraction had a higher risk of nonarrhythmic death or heart transplantation (hazard ratio, 11.01 [95% CI, 2.96-40.95]).CONCLUSIONS: Patients with tetralogy of Fallot and an ICD experience high rates of appropriate therapies, including those implanted in primary prevention. The considerable long-term burden of ICD-related complications, however, underlines the need for careful candidate selection. A combination of easy-to-use criteria including QRS fragmentation might improve risk stratification. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03837574.
KW - Adult
KW - Defibrillators, Implantable/trends
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Registries
KW - Tetralogy of Fallot/epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85094932680&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.120.046745
DO - 10.1161/CIRCULATIONAHA.120.046745
M3 - Article
C2 - 32998542
SN - 0009-7322
VL - 142
SP - 1612
EP - 1622
JO - Circulation
JF - Circulation
IS - 17
ER -